Mobble
Health · Drug development · published 2026-08-26 · via Endpoints News

Biohaven partners with SK Biopharmaceuticals on epilepsy drug in $795M deal

Biohaven has entered a licensing agreement with South Korea's SK Biopharmaceuticals for its epilepsy drug candidate. The deal could be worth up to $795 million, covering global rights to Biohaven's Kv7 ion channel platform. The partnership aims to commercialize the late-stage therapy.

Read the full article at Endpoints News →
Related stories
Roche pays $190M upfront for Hanmi's muscle-sparing obesity drug · Drug development
Lilly invests up to $370M in OmniAb ion channel partnership; Slate and Fulcrum to merge · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source. Original headline: “Biohaven strikes $795M deal for commercial partner in epilepsy.” Browse more stories.